Plasma-Derived Exosome Proteins as Novel Diagnostic and Prognostic Biomarkers in Neuroblastoma Patients.
biomarkers
exosomes
neuroblastoma
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
25 Oct 2023
25 Oct 2023
Historique:
received:
01
06
2023
revised:
18
10
2023
accepted:
20
10
2023
medline:
13
11
2023
pubmed:
10
11
2023
entrez:
10
11
2023
Statut:
epublish
Résumé
Neuroblastoma (NB) is the most common extracranial solid tumor during infancy, causing up to 10% of mortality in children; thus, identifying novel early and accurate diagnostic and prognostic biomarkers is mandatory. NB-derived exosomes carry proteins (Exo-prots) reflecting the status of the tumor cell of origin. The purpose of this study was to characterize, for the first time, the Exo-prots specifically expressed in NB patients associated with tumor phenotype and disease stage. We isolated exosomes from plasma specimens of 24 HR-NB patients and 24 low-risk (LR-NB) patients at diagnosis and of 24 age-matched healthy controls (CTRL). Exo-prot expression was measured by liquid chromatography-mass spectrometry. The data are available via ProteomeXchange (PXD042422). The NB patients had a different Exo-prot expression profile compared to the CTRL. The deregulated Exo-prots in the NB specimens acted mainly in the tumor-associated pathways. The HR-NB patients showed a different Exo-prot expression profile compared to the LR-NB patients, with the modulation of proteins involved in cell migration, proliferation and metastasis. NCAM, NCL, LUM and VASP demonstrated a diagnostic value in discriminating the NB patients from the CTRL; meanwhile, MYH9, FN1, CALR, AKAP12 and LTBP1 were able to differentiate between the HR-NB and LR-NB patients with high accuracy. Therefore, Exo-prots contribute to NB tumor development and to the aggressive metastatic NB phenotype.
Identifiants
pubmed: 37947594
pii: cells12212516
doi: 10.3390/cells12212516
pmc: PMC10649754
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Association for Cancer Research
ID : IG-17459
Références
Clin Transl Med. 2022 Oct;12(10):e1067
pubmed: 36178089
Breast Cancer Res. 2019 Feb 6;21(1):21
pubmed: 30728048
Biochim Biophys Acta. 2015 Feb;1853(2):388-95
pubmed: 25450971
Children (Basel). 2021 May 29;8(6):
pubmed: 34072462
Sci Rep. 2019 May 22;9(1):7679
pubmed: 31118506
Front Med. 2017 Dec;11(4):522-527
pubmed: 28744793
Exp Mol Pathol. 2018 Dec;105(3):364-370
pubmed: 30385176
Matrix Biol. 2021 Jan;95:1-14
pubmed: 33065248
Proteomics. 2017 Dec;17(23-24):
pubmed: 28722341
Sci Rep. 2023 Mar 27;13(1):4987
pubmed: 36973292
Gigascience. 2019 Feb 1;8(2):
pubmed: 30698691
Nucleic Acids Res. 2016 Jan 4;44(D1):D447-56
pubmed: 26527722
Sci Prog. 2022 Jul-Sep;105(3):368504221109212
pubmed: 35775596
Onco Targets Ther. 2019 Oct 08;12:8301-8310
pubmed: 31632079
BMC Nephrol. 2021 Jun 1;22(1):204
pubmed: 34074247
Membranes (Basel). 2022 May 06;12(5):
pubmed: 35629824
Dis Model Mech. 2020 Sep 18;13(9):
pubmed: 32620541
Cancer Res. 2018 Feb 1;78(3):830-839
pubmed: 29187407
FEBS Lett. 2014 Nov 28;588(23):4319-24
pubmed: 25304424
J Clin Med. 2019 Mar 18;8(3):
pubmed: 30889786
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
Nat Genet. 2017 Aug;49(8):1261-1266
pubmed: 28650485
BMC Bioinformatics. 2015 May 22;16:169
pubmed: 25994840
J Surg Oncol. 2012 Mar 15;105(4):381-6
pubmed: 22052684
J Transl Med. 2020 Mar 26;18(1):139
pubmed: 32216815
Oncol Lett. 2017 Mar;13(3):1256-1263
pubmed: 28454243
Front Immunol. 2023 Apr 27;14:1134747
pubmed: 37205098
Clin Med Res. 2004 Aug;2(3):147-50
pubmed: 15931350
Semin Oncol. 2019 Jun;46(3):284-290
pubmed: 31488338
Nat Methods. 2014 Mar;11(3):319-24
pubmed: 24487582
Cancers (Basel). 2021 Jun 25;13(13):
pubmed: 34202272
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Bioinformatics. 2012 Jan 1;28(1):112-8
pubmed: 22039212
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
Ther Adv Hematol. 2020 Feb 3;11:2040620719899818
pubmed: 32071709
J Control Release. 2017 Mar 10;249:162-172
pubmed: 28159518
Sci Rep. 2018 Jan 12;8(1):663
pubmed: 29330539
Lab Invest. 2020 Jun;100(6):812-823
pubmed: 31949244
Glycoconj J. 2004;19(7-9):551-6
pubmed: 14758079
Commun Integr Biol. 2011 May;4(3):267-75
pubmed: 21980556
Pediatr Surg Int. 2008 Dec;24(12):1361-4
pubmed: 18972120
Cancer Res. 2003 Sep 1;63(17):5344-51
pubmed: 14500366
Cancer Manag Res. 2020 Apr 01;12:2415-2425
pubmed: 32280277
Brief Bioinform. 2011 Sep;12(5):498-513
pubmed: 21156727
EBioMedicine. 2022 Nov;85:104300
pubmed: 36209521
Int J Mol Sci. 2020 Jan 06;21(1):
pubmed: 31935918
Nat Genet. 2018 Apr;50(4):515-523
pubmed: 29379199
Nature. 2013 Sep 19;501(7467):355-64
pubmed: 24048068
Biology (Basel). 2022 Mar 31;11(4):
pubmed: 35453742
Cell Res. 2021 Jan;31(1):5-16
pubmed: 32733014
Genome Biol. 2019 Oct 9;20(1):203
pubmed: 31597578
Biomedicines. 2021 Oct 01;9(10):
pubmed: 34680490
Front Immunol. 2020 Aug 18;11:1757
pubmed: 33013829
PLoS One. 2013 Sep 19;8(9):e75054
pubmed: 24069378
Int J Mol Sci. 2021 Dec 28;23(1):
pubmed: 35008754
Curr Opin Cell Biol. 2000 Apr;12(2):217-21
pubmed: 10712918
Front Immunol. 2019 Apr 04;10:712
pubmed: 31019517
Cancers (Basel). 2019 Sep 30;11(10):
pubmed: 31575060
Oncogene. 2006 Jul 20;25(31):4341-9
pubmed: 16518410
Int J Mol Sci. 2021 Apr 12;22(8):
pubmed: 33921337